Anticonvulsant valproate reduces seizure-susceptibility in mutant Drosophila

Brain Research

Volumn 958, Issue 1, 2002, Pages 36-42

  Kuebler, Daniel ^a   Tanouye, Mark ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drosophila; Epilepsy; Genetics of seizure disorders; Seizure; Seizure suppression; Valproate

Indexed keywords

VALPROIC ACID;

ANTICONVULSANT ACTIVITY; ARTICLE; ASSAY; CONTROLLED STUDY; DROSOPHILA; EVALUATION; GENE MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEIZURE; SEIZURE SUSCEPTIBILITY;

ACTION POTENTIALS; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA MELANOGASTER; ELECTRIC STIMULATION; EPILEPSY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MOTOR NEURONS; MUTATION; NERVOUS SYSTEM; NEURAL INHIBITION; SEIZURES; SYNAPTIC TRANSMISSION; VALPROIC ACID;

EID: 0037146883     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03431-5     Document Type: Article

References (35)

1. Albus H., Williamson R. Electrophysiologic analysis of the actions of valproate on pyramidal neurons in the rat hippocampal slice. Epilepsia. 39:1998;124-139.
2. Benzer S. From the gene to behavior. J. Am. Med. Assoc. 218:1971;1015-1022.
3. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 30:1989;389-399.
4. Czuczwar S., Patsalos P. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs. 15:2001;339-350.
5. Ferris G.F. External morphology of the adult. Demerec M. Biology of Drosophila. 1950;368-418 Hafner, New York.
6. Ganetzky B., Wu C.-F. Indirect suppression involving behavioral mutants with altered nerve excitability in Drosophila melanogaster. Genetics. 100:1982;597-614.
7. Godin Y., Heier L., Mark J., Mandel P. Effects of di-n-propylacetate, an anticonvulsant compound on GABA metabolism. J. Neurochem. 16:1969;869-873.
8. Greenspan R. Fly Pushing: The Theory and Practice of Drosophila Genetics. 1997;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
9. Hariton C., Ciesielsky S., Simler S., Valli M., Jadot G., Gobaille S., Mesdijan E., Mandel P. Distribution of sodium valproate and GABA metabolism in CNS of the rat. Biopharm. Drug Dispos. 5:1984;409-414.
10. Hauser W.A., Hesdorffer D.C. Epilepsy: Frequency, Causes, and Consequences. 1990;Demos, New York.
11. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem. Intl. 37:2000;103-110.
12. Kuebler D., Tanouye M.A. Modifications of seizure susceptibility in Drosophila. J. Neurophysiol. 83:2000;998-1009.
13. Kuebler D., Zhang H.G., Ren X., Tanouye M.A. Genetic suppression of seizure susceptibility in Drosophila. J. Neurophysiol. 86:2001;1211-1225.
14. Kukino K., Deguchi T. Anticonvulsant activity and effects of sodium dipropylacetate on cerebral 5-hydroxytryptamine and γ-aminobutyric acid in reserpinized mice. Chem. Pharmacol. Bull. 26:1978;3551-3555.
15. + channels. Mol. Pharmacol. 54:1998;712-721.
16. + currents: quantitative distinction from phenytoin and possible therapeutic implications. Mol. Pharmacol. 51:1997;1077-1083.
17. Leppik I.E. Intractable epilepsy: prognostic evaluation. Theodore W.H. Surgical Treatment of Epilepsy. 1992;7-11 Elsevier, Amsterdam.
18. Loscher W. Animal models of intractable epilepsy. Prog. Neurobiol. 53:1997;239-258.
19. Loscher W. Valproate: a reappraisal of it pharmacodynamic properties and mechanism of action. Prog. Neurobiol. 58:1999;31-59.
20. Loscher W., Vetter M. Relationship between drug-induced increases of GABA levels in discrete brain areas and different pharmacological effects in rats. Biochem. Pharmacol. 33:1985;1907-1914.
21. Look A., Ashmun R., Shapiro L., Peiper S. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J. Clin. Invest. 83:1989;1299-1307.
22. McLean M.J., MacDonald R.L. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J. Pharmacol. Exp. Ther. 227:1983;779-789.
23. McLean M.J., MacDonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 237:1986;1001-1011.
24. McNamara J.O. Cellular and molecular basis of epilepsy. J. Neurosci. 14:1994;3413-3425.
25. McNamara J.O. Emerging insights into the genesis of epilepsy. Nature. 399:(Suppl.):1999;A15-A22.
26. Pavlidis P., Ramaswami M., Tanouye M.A. The Drosophila easily shocked gene: a mutation in a phospholipid pathway causes seizure, neuronal failure, and paralysis. Cell. 79:1994;23-33.
27. Pavlidis P., Tanouye M.A. Seizures and failures in the giant fiber pathway of Drosophila bang-sensitive paralytic mutants. J. Neurosci. 15:1995;5810-5819.
28. Puranam R.S., McNamara J.O. Seizure disorders in mutant mice: relevance to human epilepsies. Curr. Opin. Neurobiol. 9:1999;281-287.
29. Schmidt D. Diagnostic and therapeutic management of intractable epilepsy. Schmidt D., Morselli P.L. Intractable Epilepsy: Experimental and Clinical Aspects. 1986;237-258 Raven Press, New York.
30. Tanouye M.A., Wyman R.J. Motor outputs of the giant nerve fiber in Drosophila. J. Neurophysiol. 44:1980;405-421.
31. Thomas A.B., Mathews G.C., Ferrendelli J.A. Mechanisms of action of antiepileptic drugs. Wyllie E. The Treatment of Epilepsy: Principles and Practice. 2nd Edition:1996;700-711 Williams and Wilkins, Baltimore, MD.
32. 2 mutation disrupts electrical synapses in a flight circuit in adult Drosophila. J. Neurosci. 17:1997;4700-4710.
33. + currents in cultured hippocampal cells. Exp. Brain Res. 93:1993;279-287.
34. Walton L. Essentials of Neurology. 6th Edition:1989;77-86 Churchill Livingstone, London.
35. H.G. Zhang, J. Tan, E. Reynolds, D. Kuebler, S. Faulhaber, M.A. Tanouye, The Drosophila Slamdance Gene: A mutation in an Aminopeptidase Can Cause Seizure, Paralysis and Neuronal Failure, Genetics, in press.